3 completed, 3 unknown, 1 not yet recruiting, 1 recruiting. 3 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow albuvirtide: new trials by email Literature Review of albuvirtide trials Research Report on albuvirtide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma Oral Antiretroviral Therapy, albuvirtide, Cabotegravir/Rilpivirine - AIDS-related Lymphoma, HIV Infection | Not applicable | Recruiting | Shanghai Public Health Clinical Center | 60 | 2026-05-26 | 2026-07-27 |
| Research on the Psychological Status of Patients With HIV-1 Infection All kinds of INSTI medications, All kinds of conventional medications - HIV-1-infection, Anxiety Depression | Not yet recruiting | Shanxi Bethune Hospital | 500 | 2025-08-01 | 2025-07-23 | |
| Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection Albuvirtide - HIV/AIDS | Phase 1 | Completed | Frontier Biotechnologies Inc. | 30 | 2022-02-16 | 2023-01-09 |
| Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection Albuvirtide, 3BNC117 Antibody - HIV/AIDS | Phase 2 | Unknown | Frontier Biotechnologies Inc. | 20 | 2021-11-30 | 2021-09-29 |
| Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection Albuvirtide, 3BNC117 - HIV/AIDS | Phase 2 | Unknown | Frontier Biotechnologies Inc. | 24 | 2021-05-01 | 2021-03-26 |
| The Drug Interaction Between Albuvirtide (ABT) and Rifampin（RIF） in Healthy Adult Subjects ABT, RIF - Drug Interaction | Phase 4 | Completed | Shanghai Public Health Clinical Center | 24 | 2019-07-11 | 2021-09-24 |
| Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects Albuvirtide, 3BNC117, Baseline ART - HIV-1-infection | Phase 2 | Unknown | Frontier Biotechnologies Inc. | 80 | 2018-12-17 | 2021-09-29 |
| Test Albuvirtide in Experienced Patients albuvirtide, lopinavir-ritonavir, tenofovir - HIV Infections, AIDS | Phase 3 | Completed | Frontier Biotechnologies Inc. | 418 | 2014-02-19 | 2021-10-06 |
Acquired Immunodeficiency Syndrome (4) · HIV Infections (2) · Lymphoma, AIDS-Related (1)
Frontier Biotechnologies Inc. (5) · Shanghai Public Health Clinical Center (2) · Shanxi Bethune Hospital (1)
China (5) · United States (2)
Cheng Yao (1) · Cheng Yao, M.D. (1) · Dong Xie (1) · Hongzhou Lu, Ph.D (1) · Xingyu Li, doctor (1)
PMID 33252379, PMID 33540057, PMID 38427337, PMID 41429707, PMID 41896772